RhBMP-2 vs. Autograft for Delayed Treatment of Critical Size Tibial Defects: A Multicenter Randomized Trial.

Trial Profile

RhBMP-2 vs. Autograft for Delayed Treatment of Critical Size Tibial Defects: A Multicenter Randomized Trial.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Dibotermin alfa (Primary)
  • Indications Fracture
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
    • 10 Jan 2017 Status changed from recruiting to discontinued.
    • 29 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top